Critical Limb Ischemia Treatment Market to Grow with a CAGR of 7.32% through 2029
Rising prevalence of
diabetes brought on by an aging global population is expected to drive the
Global Critical Limb Ischemia Treatment Market growth in the forecast period,
2025-2029.
According to
TechSci Research report, “Critical Limb Ischemia Treatment Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”,
the Global Critical Limb Ischemia Treatment Market stood at USD 4.02 Billion in
2023 and is anticipated to project robust growth in the forecast period with a
CAGR of 7.32% through 2029. The critical limb ischemia market is poised for growth driven by escalating diabetes rates spurred by a progressively aging global populace and advancements in critical limb ischemia treatment modalities. Despite the intricacies and limited awareness surrounding the disease, enterprises are actively engaged in the development of medications catering to the unmet demands of this condition. Inadequate identification and treatment of the condition result in heightened morbidity, mortality, and expenses. Limited awareness and the similarity of symptoms with other diseases hinder the growth of the critical limb ischemia market. Additionally, setbacks in medication development, stringent pricing and reimbursement regulations, and limited accessibility to surgical techniques pose challenges for the advancement of novel treatments in the critical limb ischemia market.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Critical Limb Ischemia Treatment Market”
The limited understanding
of the disease's epidemiology and etiology has hindered the development of
effective therapeutic options. Consequently, key market players in critical
limb ischemia treatment have experienced a decline in revenue during the pandemic.
However, the market has been recovering post-COVID-19, primarily due to
regulatory relaxations implemented by governments worldwide. During the
forecast period, it is projected that the devices segment will hold a
substantial share of the global critical limb ischemia therapy market. Stents
and dilation devices play a crucial role in artery dilation while ensuring the
safety of the arterial wall. These tools are commonly utilized in treating
critical limb ischemia, leading to improved patient quality of life attributed
to low complication rates and high technical success rates. The anticipated
growth of the devices segment during the forecast period is expected to be
driven by these benefits. Additionally, factors such as the increasing number
of FDA approvals and patient preference for revascularization as the primary
treatment approach contribute to the dominance of this segment.
The Global Critical
Limb Ischemia Treatment Market is segmented into Treatment, Region and company.
In the Devices segment, the Embolic Protection Devices segment
is expected to show significant market expansion in the forecast period,
driving the growth of the Global Critical Limb Ischemia (CLI) Treatment Market.
This growth is fueled by the widespread acceptance of Embolic Protection
Devices (EPDs), which are crucial in improving the safety and effectiveness of
endovascular interventions for critical limb ischemia. EPDs play a vital role
in preventing the migration of embolic debris during procedures.
In the Drugs segment, the
Antihypertensive Agents category has emerged as the leading force in the
market. The Global Critical Limb Ischemia (CLI) Treatment Market is seeing
growth due to the essential role of Antihypertensive Agents in maintaining
vascular health. These medications, designed to reduce blood pressure, are
critical in preventing and managing conditions associated with critical limb
ischemia. Hypertension presents a significant risk for vascular diseases,
making the control of blood pressure crucial in preventing further decline of
peripheral arteries. As physicians increasingly acknowledge the importance of
managing cardiovascular risk factors in CLI patients, antihypertensive agents
have become integral components of comprehensive treatment plans.
Major companies
operating in Global Critical Limb Ischemia Treatment Market are:
- Medtronic plc
- LimFlow SA
- Cynata Therapeutics
Ltd
- Cardiovascular
Systems, Inc.
- Eli Lilly and
Company
- Abbott Laboratories, Inc.
- Rexgenero Ltd.
- Cesca Therapeutics
(ThermoGenesis Holdings, Inc)
- Teva Pharmaceuticals Industries Limited
- Micro Medical
Solutions
- Boston Scientific
Corporation
Download Free Sample Report
Customers can
also request 10% free customization on this report
“Moreover, the increasing prevalence of risk factors contributing to critical limb ischemia (CLI) incidence is poised to drive market growth. Market players are implementing diverse strategies including product launches, mergers and acquisitions, and product development to bolster market expansion during the forecast period. Heightened company endeavors towards the development of bone graft substitute products, alongside the adoption of various business strategies such as collaborations, mergers, and acquisitions, are all expected to further stimulate market growth throughout the forecast period. The increasing focus of the company to
develop technologically advanced devices and drugs to treat critical limb
ischemia is expected to augment the growth of the market.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Critical Limb Ischemia Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment
(Drugs, Devices), By Drugs (Antiplatelet Drugs, Antihypertensive Agents,
Lipid-lowering Agents, Antithrombotic Agents, Others), By Devices (Embolic
Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular
Stents), By Region, By Competition, 2019-2029F”, has evaluated the future growth potential of Global
Critical Limb Ischemia Treatment Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Critical Limb Ischemia Treatment Market.
Contact
TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com